‘Alunbrig’ – A named patient medicine for NSCLC

Non-small cell lung cancer is a common cancer, accounting for about 80%-85% of all lung cancer cases. It is one of the leading causes of death in the United States. With in-depth research on the reasons behind lung cancer, cell biology has developed small drugs that can interrupt certain gene mutations and treat patients with NSCLC.

According to research, many of the driving factors for this tumor mutation are 10% EFGR mutation, 23% KRAS mutation and 13% ALK mutation. Realize that certain types of mutations will lead to correct handling in the process.

Among various treatments, the FDA expanded its approval for Alunbrig on April 28, 2017. It is a new generation of ALK inhibitors, mainly approved for the treatment of ALK-positive metastatic NSCLC. The drug is effective when crizotinib is ineffective or does not produce a positive reaction.

Oncology supports Alunbrig because half of the 222 patients who used the drug in clinical trials experienced a nearly 30% cancer reduction. It has similar effects on men and women. However, you must pay attention to the following points before taking Alunbrig:

    For men-For men whose partners are in reproductive health, contraceptives should be used during treatment and at least 3 months after taking the last dose.
    For women-Women who are effectively pregnant should take non-hormonal contraceptives during treatment and should continue to take them until the final dose of 4 months.

The Pharmaceuticals consulting services introduced Alunbrig to named patient medicine because it has not been widely used and is named a patient drug.